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Abstract: Fused deposition modeling (FDM) three-dimensional (3D) printing is being increasingly 
explored as a direct manufacturing method to product pharmaceutical solid dosage forms. Despite 
its many advantages as a pharmaceutical formulation tool, it remains restricted to proof-of-concept 
formulations. The optimization of the printing process in order to achieve adequate precision and 
printing quality remains to be investigated. Demonstrating a thorough understanding of the 
process parameters of FDM and their impact on the quality of printed dosage forms is undoubtedly 
necessary should FDM advance from a proof-of-concept stage to an adapted pharmaceutical 
manufacturing tool. This article describes the findings of an investigation into a number of critical 
process parameters of FDM and their impact on quantifiable, pharmaceutically-relevant measures 
of quality. Polycaprolactone, one of the few polymers which is both suitable for FDM and is a 
GRAS (generally regarded as safe) material, was used to print internally-exposed grids, allowing 
examination of both their macroscopic and microstructural reproducibility of FDM. Of the 
measured quality parameters, dimensional authenticity of the grids was found to poorly match the 
target dimensions. Weights of the grids were found to significantly vary upon altering printing 
speed. Printing temperature showed little effect on weight. Weight uniformity per batch was found 
to lie within acceptable pharmaceutical quality limits. Furthermore, we report observing a 
microstructural distortion relating to printing temperature which we dub The First Layer Effect 
(FLE). Principal Component Analysis (PCA) was used to study factor interactions and revealed, 
among others, the existence of an interaction between weight/dosing accuracy and dimensional 
authenticity dictating a compromise between the two quality parameters. The Summed Standard 
Deviation (SSD) is proposed as a method to extract the optimum printing parameters given all the 
perceived quality parameters and the necessary compromises among them. 
Keywords: Fused Deposition Modeling 3D Printing; processing parameters; pharmaceutical 
quality control; hot-melt extrusion; solid dosage forms 
 
1. Introduction 
Three-dimensional (3D) printing continues to attract increasing attention in the pharmaceutical 
industry [1]. The flexibility and customisability potential offered by 3D printing promises to 
overcome some limitations of traditional pharmaceutical manufacturing techniques, particularly for 
personalised medicine [2]. The successful commercialisation of Spritam® 3D printed levetiracetam 
tablets, which are produced by powder-jetting 3D printing, further cemented the prospects of 3D 
printing as a realistic technique for pharmaceutical manufacturing [3]. Several variants of 3D 
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printing exist. Khaled et al. demonstrated the use of semi-solid extrusion 3D printing to fabricate 
5-in-1 polypills [4]. Awad et al. used selective laser sintering to 3D print ibuprofen-paracetamol 
bilayered pellets [5]. Robles-Martinez et al. used stereolithographic 3D printing to print stratified 
polypills containing six drugs [6]. Fused Deposition Modelling (FDM) is another type of 3D printing 
variant that has been increasingly investigation for pharmaceutical exploration [1,7]. FDM is an 
inexpensive and very widely available technique compared to other variants of 3D printing. The 
pairing of FDM with Hot-Melt Extrusion (HME) [8–10] extends the library of available materials for 
3D printing to include many pharmaceutically-relevant polymers, allowing for material flexibility 
when formulating a pharmaceutical product. Furthermore, FDM is not liable to some of the 
limitations posed by other 3D printing variants. Objects produced by powder-based 3D printing and 
semi-solid extrusion are susceptible to mechanical weakness issues [7,11]. Stereolithography relies 
on ultraviolet curing to fabricate the object, which raises drug stability and safety concerns [7]. 
Because of those reasons, an increasing number of publications suggests that FDM may be a 
favourable 3D printing method for the fabrication of personalized medicines in the form of solid 
dosage forms [8,11–18]. It was demonstrated that even off-the-shelf FDM printers are capable of 
producing proof-of-concept formulations. 
There is currently no FDM printer that has been specifically designed for pharmaceutical 
applications. Commercially available printers, such as the MakerBot® brand of printers, designed for 
fabricating plastic material-based prototype objects, have been frequently reported as the printers 
used when fabricating pharmaceutical dosage forms by FDM [1,8,9,14–16,18–20]. When 
characterizing the FDM printed objects, the non-pharmaceutical literature is largely concerned with 
the surface roughness and tensile strength of the fabricated objects [21–25]. In pharmaceutical 
applications, when the FDM printed objects are intended to be used as oral solid dosage forms, 
achieving precise and highly reproducible dimensions and weight is critical. However, to date, there 
is no debate on whether the fundamental design of these prototype-building FDM printers is 
suitable for pharmaceutical manufacturing. This study performed a detailed investigation of the 
influences of the processing parameters on the key quality attributes of the printed objects, including 
uniformity, reproducibility, and adherence to design specifications required for the pharmaceutical 
standards. 
Although this study is limited to one particular printing machine it is intended to indicate the 
design parameters that must be considered when producing a 3D FDM printer for clinical 
pharmaceutical applications 
In the FDM printing process, and any printing process, the quality of the printed object is the 
result of a complex interplay between the properties of the printing material and the settings of the 
machine (both adjustable and non-adjustable), the relevant parameters for FDM printing are shown 
in Figure 1. For the printer used in this work, the machine adjustable parameters are print speed, 
extrusion temperature, build plate temperature, and layer thickness. These represent the main 
variables in the FDM printing process. Temperature will necessarily affect the material properties, in 
particular, its rheological properties [26]. These, in turn, will determine the flow out of the printing 
head, often known as melt flow, which is one of the factors investigated in this study, and the spread 
on the build plate, which may then affect the reproducibility and dimensional precision of the 
printed object. Under some circumstances, high temperature may increase the fluidity of the 
printing material and cause unstable layer deposition. At the other extreme, low temperatures may 
cause reduced flow resulting in the print head, resulting in a blockage or a flow rate too small to 
print adequately at some printing speeds. Rheology may also affect flow after deposition on the 
build plate. In this work, we examine the interaction of the machine adjustable parameters and the 
print material rheological properties as indicated by the melt flow index and their effect on the 
reproducibility and adherence to design specification of the printed object. We note that some 
research suggests that computational factors such as slicing (the process by which the 
computer-generated 3D model is translated into movement instructions for the printer motors) 
algorithms could play a significant role in the overall quality of the printed object [27,28]. In this 
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work, we restrict ourselves to exploring the relevant physical parameters, as other parameters 
cannot be manipulated without physically modifying the machine. 
 
Figure 1. Summary of the interactions between the materials properties and the machine and process 
parameters in a fused deposition modeling (FDM) three-dimensional (3D) printing process. 
In addition, prior to the printing process, the ‘leveling’ of the printer, which is to ensure that the 
distance between the printing head and the build plate is constant across the printing area, should be 
performed to ensure the reproducible quality of the printed objects. It has been reported [8] that, for 
a machine of the same make and model, the outcome of this process could be operator dependent, 
indicating that the printing outcome may be irreproducible between operators. We report below on 
our examination of this problem. 
Polycaprolactone (PCL), being one of the very few polymers approved for pharmaceutical use 
that is also suitable for FDM without further formulation [9,19], was used as the model polymer to 
investigate the effect of material and process parameters on the quality of printing. In the course of 
the work, it was noted that the first deposited layer tended to have different morphology to the 
layers above. We have dubbed this phenomenon The First Layer Effect (FLE). Apart from the 
variables discussed above, it is possible that the surface properties of the build plate may affect the 
first layer so the printing behaviour on different surfaces was also investigated. This is expected to 
have great importance for selecting the best build plate lining that allows the most suitable 
adherence of the printing material to the build plate during the building process and provides the 
easy peel-off of the object after the complete production of the printed dosage forms. 
2. Materials and Methods 
2.1. Materials 
PCL commercial filament was purchased from MakerBot Industries (MakerBot Industries LLC., 
New York, NY, United States). PCL pure powder (CAPA™, Grade 6506) was purchased from 
Perstorp Chemicals (Perstorp Chemicals GmbH, Arnsberg, Germany), acetylsalicylic acid (ASA) was 
purchased from Sigma Aldrich (Sigma Aldrich Ltd., Dorset, United Kingdom). 
2.2. Methods 
2.2.1. Preparation of Drug Loaded Filaments by HME 
Three drug loaded PCL filaments containing 5%, 10%, and 15% ASA were prepared using 
HME. For each batch of the filament, the power mixes were accurately weighed then thoroughly 
mixed using a mortar and pestle. The powder mixes were fed into a Haake II minilab compounder 
(Thermo Scientific, Karlsruhe, Germany) equipped with a co-rotating twin screw set and a circular 
die with a diameter of 1.75 mm. Extrusion was performed at 100 °C with a screw rotation speed of 
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100 revolutions per second (RPM). All formulations were cycled in the extruder for 5 min to ensure 
homogeneous mixing of ASA and PCL prior to being flushed out. 
2.2.2. FDM 3D Printing of Commercial Filaments and Drug-Loaded Filaments 
A MakerBot Replicator 2X twin nozzle desktop 3D printer (MakerBot Industries LLC, New 
York, NY, United States), equipped with nozzles of diameter 400 µm, was used for printing all 
filaments. The solid dosage form used in this study was a three-layered square film with 25 mm in 
length and width, and 0.6 mm in thickness (with 0.2 mm thickness per layer) (Figure 2). The film is 
comprised of 31 identical rods (rod dimensions: 0.4 mm wide, 0.2 mm thick, and 25 mm long). The 
design of the film is illustrated in Supplementary Materials Figure S1. The film was designed using 
Blender software and was then exported in stereolithography file format (STL file). The STL file was 
printed using MakerBot MakerWare™. 
 
Figure 2. Macroscopic (left) and light microscopy image (right) of the 3D printed film. 
Twelve sets of different printing experiments were conducted, each varying either one of three 
factors (nozzle temperature, build plate temperature, and printing speed), as seen in Table 1. Five 
films were printed using each set of printing parameters, the printed film was weighed and the 
dimensions of the films were then accurately measured using a digital calliper. Printing of the 
drug-loaded filaments was performed using the MakerBot Replicator 2X printer. The filaments were 
printed with a nozzle temperature of 100 °C, an unheated build plate and were printed at a speed of 
90 mm/s. 
Table 1. Experimental parameters used for printing the selected 3D object using MakerBot® Flexible 
filament. 
Nozzle Temperature (°C) Platform Temperature (°C) Printing Speed (mm/s) 
100 30 30 
100 30 90 
100 30 160 
110 30 30 
110 30 90 
110 30 160 
120 30 30 
120 30 90 
120 30 160 
100 45 30 
100 45 90 
100 45 160 
2.2.3. In Vitro Drug Release Studies 
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ASA release studies from the 5%, 10%, and 15% loaded 3D printed grid films were conducted 
using the United States Pharmacopoeia (USP) apparatus II (paddle) using a revolution rate of 50 
RPM. The grids were placed in 750 mL of pH 1.2 simulated gastric fluid for 2 h, then transferred to 
900 mL of pH 6.8 phosphate buffer saline. Determination of amount of ASA released was conducted 
using a Perkin Elmer Lambda 35 UV/Vis spectrophotometer (PerkinElmer, Inc., Waltham, MA, 
United States) at a wavelength of 265 nm [29]. 
2.2.4. Melt Flow Index Measurements 
The melt flow index (MFI) of the filaments was measured using an adaptation of the ISO 1133-1 
standard method [30]. The printing head of a MakerBot® Replicator 2X desktop FDM 3D printer 
(MakerBot Industries LLC. New York, NY, United States) was detached from its roller feeding zone 
and used to melt the filaments. A piston attached to a metal weight of 80 g was used to propel 2 cm 
slices of the filament through the nozzle (Supplementary Materials Figure S2). The filament melt 
flowing from the nozzle was collected at specified time intervals and weighed. The mass of the 
polymer (in milligrams) extruded per second was regarded as the MFI of the polymer. Using this 
adapted method maintains the gravimetric flow of the polymer melt that is characteristic of standard 
MFI measurements, but over the relevant capillary diameter of the printing nozzle. The MFI 
measurements for PCL were performed using a temperature range of 70 ºC to 130 ºC. 
The quantity (in milligrams) of material deposited per second during an actual FDM printing 
process is defined in this study as the FDM-MFI. The FDM-MFI values of the PCL filaments were 
measured at three different printing speeds (30 mm/s, 90 mm/s, and 160 mm/s) over a range of 
processing temperatures (70–130 °C). For both MFI and FDM-MFI measurements, the rate of 
deposition of the objects was then expressed as weight deposited per unit time (mg/min). 
2.2.5. Leveling of the Build Plate of the Printer 
Two investigations of the platform leveling were performed. Inter-person calibration: the 
platform was leveled by two operators, then six square films were printed and their weights and 
dimensions quantified. Same person inter-day calibration: the platform was leveled by the same 
operator on two different days; then, a set of six squares were printed and their weights and 
dimensions were quantified. The object used for calibration was a simple square design with an edge 
length of 10 mm and a thickness of 1 mm printed using standard printer settings at 100 ºC. 
Leveling was conducted as per the standard printer leveling procedure outlined in the user 
manual of the printer [31]. The card supplied with the instrument was placed between the nozzle 
and the build plate at various positions around the build plate and the leveling screws were adjusted 
until the card can just slide between the build plate and the nozzle. 
2.2.6. Printing on Different Surfaces 
The FLE was further investigated by printing the PCL films on three different surfaces, Kapton® 
(polyimide) Tape, aluminum, and glass. Aluminum and glass were secured to the build plate using 
double adhesive tape, to ensure that there was no movement of the test surface during printing. All 
of these printing experiments were conducted using a nozzle temperature of 100 °C and a printing 
speed of 90 mm/s. The build plate was leveled following the protocol described in 2.2.4 before each 
printing attempt. 
2.2.7. Characterization of Printed Solid Dosage Forms 
Microscopic images were acquired using a Linkam Imaging Station, equipped with a Linkam 
MDS600 heating/cooling stage (Linkam Scientific Instruments, Tadworth, United Kingdom). Image 
analysis (dimensions measurements) was conducted using LINK software version 1.0.5.9 (Linkam 
Scientific Instruments, Tadworth, United Kingdom) to measure the road widths of the 3D printed 
objects. 
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Fourier-Transform Infrared (FTIR) spectroscopy was used to characterize all materials used in 
this study. Spectra were acquired using a Vertex 70 infrared spectrometer (Bruker Optics Ltd., 
Coventry, United Kingdom), equipped with Golden Gate, heat-enabled Attenuated Total 
Reflectance (ATR) accessory (Specac Ltd., Orpington, United Kingdom) fitted with a diamond 
internal reflection element. The spectra were acquired in absorbance mode, with a resolution of 2 
cm−1, and 32 scans per sample. Scanning range was set to 4000 cm−1–600 cm−1. Spectral analysis was 
conducted using OPUS software, version 7.8 (Bruker Optics Ltd., Coventry, United Kingdom). 
Differential Scanning Calorimetry (DSC) was carried out using a TA Universal Q2500 
Discovery series DSC (TA Instruments, Newcastle, DE, United States). DSC was used to characterize 
the pure materials (PCL commercial filament, PCL powder, and ASA powder), the physical mixes, 
and extruded filaments. PCL powder was characterized using a heat-cool-reheat method with a 
range from 20 °C to 120 °C, followed by cooling to −90 °C, then reheating to 120 °C. ASA powder and 
physical mixes of all three formulations were scanned using a heat-cool-reheat method; samples 
were tested over a range of 20 °C to 150 °C, then cooled to −90 °C, and then reheated to 150 °C. All 
extruded filaments were characterized using a heat-cool-reheat method using a temperature range 
of −90 °C to 150 °C. A heating/cooling rate of 10 °C/min was used for all experiments. All samples 
were equilibrated for 3 min at either 20 °C or −90 °C at the start of each experiment. All 
characterization experiments were carried out in triplicates. 
2.2.8. Statistical Analysis 
Independent sample T-tests were conducted using Microsoft Excel (version 2016) expanded 
with the statistical data analysis add-on. 
Summed Standard Deviation (SSD) was calculated as follows: for each value of temperature (T) 
and speed (S) the normalised standard deviations (𝑃ᇱ) of the measured parameters weight (M), 
length (L), width (W), thickness (D), and road width (R), were calculated using the following 
equation: 
𝑃௜ᇱ = (ఙ೔೛௉೔ )்,ௌ (Equation (1)) 
where 𝑃௜ is the value of the measured parameter at a fixed value of S and T and 𝜎௜௣ is its standard 
deviation. These were summed up, as shown in Equation (2): 
𝑆𝑆𝐷 =  ∑ [𝑃ᇱெ +ௌୀ௡்ୀ௡ௌୀ଴
்ୀ଴
𝑃ᇱ௅ + 𝑃ᇱௐ + 𝑃ᇱ஽ + 𝑃ᇱோ]்,ௌ (Equation (2)) 
Principal Component Analysis (PCA) was conducted on all the measured responses using IBM® 
SPSS statistics (version 25). Following the Kaiser criterion, only principal components with an 
eigenvalue ≥ 1 were extracted (n = 2), yielding a total explained variance of 82.15% (Principal 
Component 1: 57.77%. Principal Component 2: 24.38%). The unrotated components matrix showed 
no factor that could be explained solely by either principal component (coefficient < 0.4); therefore, 
Varimax rotation was conducted such that each factor is solely described by a single principal 
component. The loadings plot was used to extract variable scores for each of the two factors 
(printing temperature, and printing speed), the scores were imported into Microsoft Excel and used 
to generate a biplot [32,33]. 
3. Results and Discussion 
3.1. Impacts of Build Plate Leveling 
It has been previously reported in the literature that the leveling of the build plate of MakerBot® 
printers causes a significant difference in the weights of the 3D printed objects when conducted by 
different operators [8]. In an attempt to prevent this discrepancy from misattributing other findings 
of this work, calibration prints were conducted as described in Section 2.2.5. The weights and 
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dimensions of the two sets were then compared via an Independent Sample T-Test. The results are 
shown below in Table 2 and Table 3. 
Table 2. Effect of leveling by different operators on the weight and dimensions of the printed objects. 
RSD: Relative standard deviation ((𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 ⁄𝑀𝑒𝑎𝑛) × 100). 
Operator I 
n Thickness (mm) Length (mm) Width (mm) Weight (mg) 
1 1.09 9.92 10.01 110.6 
2 1.04 10.03 10.10 114.6 
3 1.07 10.00 10.16 113.4 
4 1.05 10.00 10.09 111.0 
5 1.10 9.91 10.02 109.8 
6 1.05 9.99 10.20 111.0 
RSD 2.25% 0.48% 0.74% 1.65% 
Operator II 
n Thickness (mm) Length (mm) Width (mm) Weight (mg) 
1 1.03 10.05 10.16 107.7 
2 1.08 10.05 10.23 112.6 
3 1.04 10.06 10.13 111.1 
4 1.06 10.05 10.20 112.5 
5 1.04 9.96 10.18 108.7 
6 1.06 9.94 10.10 110.1 
RSD 1.71% 0.53% 0.46% 1.8% 
Independent Sample T-Test 
P-Value (Length) P-Value (Width) P-Value (Thickness) P-Value (Weight) 
0.223 0.101 0.127 0.137 
As seen in Table 2, the P-value for the T-tests for all of the parameters was > 0.05, indicating no 
significant difference between the objects printed when the leveling was carried out by two different 
operators. 
Table 3 shows the results of the calibration prints when the platform was leveled by the same 
operator on two different days. The P-value for width was the only T-Test parameter found > 0.05, 
indicating no significant difference. P-values for length, thickness, and weight were all < 0.05, 
indicating significant difference. 
Table 3. Inter-day variation in leveling on the weight and dimensions of the printed objects. RSD: 
Relative standard deviation ((𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 ⁄𝑀𝑒𝑎𝑛) × 100). 
Day 1 
n Thickness (mm) Length (mm) Width (mm) Weight (mg) 
1 1.09 9.92 10.01 110.6 
2 1.04 10.03 10.10 114.6 
3 1.07 10.00 10.16 113.4 
4 1.05 10.00 10.09 111.0 
5 1.10 9.91 10.02 109.8 
6 1.05 9.99 10.20 111.0 
RSD 2.25% 0.48% 0.74% 1.65% 
Day 2 
n Thickness (mm) Length (mm) Width (mm) Weight (mg) 
1 1.02 10.08 10.11 108.7 
2 1.04 10.09 10.12 108.4 
3 1.07 10.03 10.14 105.2 
4 1.03 10.06 10.11 107.9 
5 1.02 10.03 10.08 104.5 
6 1.04 10.06 10.14 109.7 
RSD 1.83% 0.25% 0.23% 1.93% 
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Day 1 
Independent Sample T-Test 
P-Value (Length) P-Value (Width) P-Value (Thickness) P-Value (Weight) 
0.004 0.213 0.04 0.006 
A study conducted by Melocchi et al. using the same model of the FDM printer [8] previously 
reported a significant difference when the build plate was leveled by different operators. We 
acknowledge that the results reported herein contradict with those findings. However, as shown in 
Table 3, we observed a significant difference (most importantly in weights of the printed objects) 
when the printer was leveled by the same operator on two different days. Both our findings and 
what was reported by Melocchi et al. serve to highlight the operator dependence of the calibration of 
this model of printer which can be a potential problem in this design of the printer if it is used for 
printing pharmaceutical standard products. The current method employed by the printer to level the 
build plate is very subjective, relying on what the operator’s judgment as ‘suitable friction’ between 
the nozzle tip and leveling card. While this may be adequate for printing large commercial prototype 
objects, it is unlikely to be a suitable ‘calibration’ method for pharmaceutical printing of oral solid 
dosage forms where high printing precision is required. Therefore, we believe that the leveling 
process of any printer to be used for manufacturing pharmaceutical standard solid dosage forms 
needs to be modified to a more robust procedure. 
3.2. Impacts of Melt Flow of the Printed Materials 
The Melt Flow Index (MFI), is defined by the ISO standard 1133-1 as “the mass of the molten 
polymer, in grams, that flows through a capillary of a specific diameter in 10 min” [30]. The MFI of a 
filament is often cited as one of the key factors defining the success of an FDM printing process 
[9,19,34]. The MFI is highly associated with the thermal viscosity of the filament materials at a 
certain printing temperature [26]. Therefore, MFI measurements (which describe the amount of PCL 
deposited due to its melt flow) were compared to the amount deposited during FDM printing 
(referred to as FDM-MFI in Figure 3b). Despite the temperature dependence of rheology seen in the 
MFI experiments (Figure 3a), there was a very weak temperature dependence of deposition rates 
when printed using FDM (Figure 3b). This implies that over the range of relevant printing 
temperatures, the change in the melt flow of the filament is not too great to significantly impact the 
amount of material being deposited by the print head. The only effect was seen at 70 ºC, where 
printing was only possible at a printing speed of 30 mm/s. This leads to the hypothesis that, 
provided that the operating speed is sufficient to allow free flow of the polymer melt, the 
contribution of operating temperature to the printability of the material is not of prime importance. 
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Figure 3. (a) The measured MFI values of the PCL filaments at different temperatures (the arrow 
indicates the manufacturer recommended printing temperature); (b) FDM-MFI of the PCL filaments 
measured at different printing speeds across different printing temperature. *: printing at 90 mm/s 
and 160 mm/s was not possible at this speed. 
3.3. Impact of Processing Conditions on Weight Uniformity. 
MFI measurements showed that PCL has measurable melt flow index at a temperature of 70 ºC; 
however, printing of PCL was only possible at this temperature at the lowest speed of 30 mm/s. In 
addition, objects printed at 80 °C and either 90 mm/s or 160 mm/s were much distorted, with very 
poor printing quality and erratic melt deposition. Therefore, samples printed at 70 °C and 80 °C were 
disregarded. This suggests that there is a lower limit to the melt flow index, below which good 
quality printing is not possible. 
Despite that, on average, the impact of the printing temperature on melt deposition rate was not 
as significant as printing speed (Figure 3b). It appears that it may impact the reproducibility of the 
weights of the printed objects. As can be seen in Figure 4a, at a fixed printing speed, increasing the 
printing temperature resulted in an increase in the weights of the printed objects. This is to be 
expected, as melt flow of PCL increases with temperature. The standard deviations of weights do 
not seem to follow any trends either with temperature or printing speed. The largest recorded 
standard deviation was ± 3.2 mg at 90 mm/s and 120 °C. The second largest being ± 3.0 mg at 30 
mm/s and 70 °C, and the third largest being ± 2.4 mg at 30 mm/s and 110 °C. Notably, fixing the 
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printing speed at 160 mm/s yields the narrowest standard deviations, with the smallest standard 
deviation at that speed being ± 0.1 mg at 100 °C, and the largest being ± 0.9 mg, seen at both 120 °C 
and 130 °C. Even though all the reported standard deviations fall well within acceptable limits for 
weight uniformity specified in the pharmacopoeias, it is worth noting that changing the printing 
conditions was seen to substantially impact weights of the printed objects, by as much as 31.3 mg. 
The lightest printed object weighed 169.1 mg (± 0.5 mg, printed at 70 °C, and 160 mm/s), and the 
heaviest printed object weighing 200.3 mg (± 1.5 mg, printed at 130 °C, and 30 mm/s). These results 
indicate that if FDM is to be utilized in personalized medicine, careful screening of the printing 
parameters, and choosing the appropriate conditions to match the target dose is of utmost 
importance [2]. 
 
Figure 4. (a) The weight; (b) the length and width; and (c) the thickness of the films printed at a range 
of speed and temperature. The dotted lines at 25 mm in (b) and 0.6 mm in (c) indicate the theoretical 
targeted values of the dimensions. 
3.4. Impact of Processing Conditions on Dimensional Authenticity 
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For the commercial printers, the pre-set (target) object parameters are dimensions instead of 
weight. Therefore, it is important to understand the effect of the process parameters by comparing 
the measured printed object dimensions to the target values pre-set by the STL file. Despite the 
source STL file being designed as a square in this study, all the objects printed displayed a difference 
between length and width. To avoid ambiguity, length was defined as the dimension parallel to the 
roads of the first layer, and width as the dimension perpendicular to the roads of the first layer. The 
impacts of the printing temperature on the dimensions (width, length, and thickness) of the objects 
are illustrated in Figure 4b and c. For each printing condition, the length of the objects was found to 
be larger than the width of the objects. The printing temperature shows no significant effect on the 
reproducibility of the length and width of the printed films at a fixed printing speed. 
Reducing the printing temperature increases the thickness of the films for both 30 and 160 mm/s 
printing speeds but there is no significant effect at the printing speed of 90 mm/s. Microscopic 
imaging of the printed films (Table S1) revealed that the road width of the first layer is much larger 
than that of the subsequent layers, and the width of the first layer appears to be correlated with the 
nozzle temperature. This correlation between first layer road width and the reduction of object 
thickness with increasing temperature suggests that when the first layer is deposited on the build 
plate, the fluid melt spreads sideways, increasing in width and decreasing in thickness, resulting in 
the observed effect on road width and thickness. We have chosen to dub this phenomenon the First 
Layer Effect (FLE), which is discussed in a further section. 
Printing at 90 mm/s and 160 mm/s yielded objects that possessed greater length and lower 
width than the target (25.29 mm ± 0.06 mm × 24.95 mm ± 0.04 mm for 90 mm/s, and 25.29 mm ± 0.11 
mm × 24.93 mm ± 0.04 mm for 160 mm/s), showing no significant difference in dimensions between 
the two conditions. However, printing at 30 mm/s yielded objects that were smaller than the target 
geometry of 25 mm × 25 mm (with the films being 24.68 mm ± 0.06 mm × 24.33 mm ± 0.11 mm). At 
this speed, no changes in length and width relative to changing the temperature were observed. In 
terms of reproducibility of lengths and widths, none of the three printing speeds showed 
remarkably different results, with no significant differences between the standard deviations of 
dimensions between the three printed conditions. 
As can be seen in Figure 4c, the thickness of the 3D printed objects tends to decrease with 
increasing temperature for both 160 mm/s and 30 mm/s, going from 0.65 mm ± 0.00 mm at 90 °C to 
0.61 mm ± 0.01 mm at 130 °C when printed at 30 mm/s, and from 0.65 mm ± 0.02 mm to 0.59 ± 0.01 
mm when printing at 160 mm/s. Objects printed at 90 mm/s had, on average, consistent thickness, 
independent of printing temperature. Furthermore, printing at 90 mm/s appears to have the most 
reproducible object thicknesses, with the narrowest recorded standard deviation at said speed being 
± 0.00 mm, and the widest being ± 0.01 mm (within the limits of detection of the digital caliper used). 
3.5. The First Layer Effect (FLE) 
Figure 5a shows the average road width of each layer under different printing conditions. The 
top layer is the closest to the nozzle. The platform layer is the bottommost layer resting on the build 
plate of the printer. No significant difference was seen between the top and middle layers of the 
objects, regardless of printing conditions. The average road width for the top layer was 347.0 µm ± 
12.00 µm at 30 mm/s, 345.0 µm ± 15.37 µm at 90 mm/s, and 323.5 µm ± 25.62 µm at 160 mm/s. The 
average road width for the middle layer was 341.3 µm ± 18.46 µm at 30 mm/s, 310.4 µm ± 13.56 µm at 
90 mm/s, 316.8 µm ± 27.45 µm at 160 mm/s. The platform layer displayed a larger road width than 
the corresponding top and middle layers at every printing condition, with the average road width of 
the platform layer being 438.8 µm ± 51.79 µm at 30 mm/s, 425.8 µm ± 34.56 µm at 90 mm/s 436.1 µm ± 
68.63 µm at 160 mm/s. 
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Figure 5. (a) Impacts of printing temperature and printing speed on the road width measurements of 
the platform (the first layer deposited on the build plate), middle, and top layer (with inserted 
microscopic image illustrating the platform and mid layers); (b) impact of different printing surfaces 
on the road width of the platform layer when printed at 90 mm/s and 100 °C. Microscopic images of 
printed films can be seen in supplementary materials Table S1. 
The road width of the platform layer was also observed to vary inversely with printing 
temperature. There was a notable decrease in the average road width of the first layer at different 
printing temperatures; at 30 mm/s, the road width increased from 402.1 µm ± 12.9 µm at 90 °C to 
517.5 µm ± 26.0 µm at 130 °C. At 90 mm/s, the road width increased from 420.5 µm ± 19.1 µm at 90 °C 
to 465.2 µm ± 14.9 µm. At 160 mm/s, the road width increased from 422.0 µm ± 35.7 µm at 90 °C to 
554.0 µm ± 55.9 µm at 130 ºC. Due to the platform layer being the first layer constructed during the 
fabrication of the object, this phenomenon has been dubbed The First Layer Effect (FLE). This 
spreading effect is assumed to be caused by the nature of the interaction of PCL with the surface of 
the Kapton® tape. Therefore, printing was attempted on different surfaces. Printing on different 
surfaces yielded different spreading amounts (Figure 5b). Building on glass was found to yield the 
narrowest average road width (322.3 µm ± 13.03 µm). Building on aluminum was found to yield the 
widest road width (419.8 µm ± 22.00 µm). The increased spreading with temperature when printing 
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on Kapton® is likely due to decreased viscosity of PCL at higher temperatures allowing it to flow 
more prior to solidifying. 
When printed at higher temperatures (> 110 °C), PCL was found to bind strongly to the Kapton® 
tape. When printed at lower temperatures (i.e., 80 °C–100 °C), the PCL films were easily removed. 
However, no sticking to aluminum or glass was observed. The temperature-dependent spreading, 
and the sticking of the objects to the Kapton® tape at elevated temperatures is probably due to the 
formation of PCL-polyimide interactions at elevated temperatures, yielding greater wetting and 
adhesion to the surface. 
3.6. Impact of Drug Incorporation 
Drug incorporation can often cause changes to the printability of polymeric filaments, in most 
cases due to the plasticisation effect of the drug when a molecular dispersion is formed between the 
drug and the polymer. Three levels of drug loading were used to create filaments that were either 
true molecular dispersions or supersaturated with the crystalline drug in the filaments. DSC and 
ATR-FTIR spectroscopy were used to characterize the physical state of the ASA in the filaments 
prepared by HME (Figure S3 and Figure 6). The results indicate the formation of a molecular 
dispersion of ASA in PCL at 5% drug loading, whereas both the 10% and 15% formulation contain a 
crystalline fraction of ASA. The shifted peaks of the C–O and C–OH groups indicate the molecular 
interaction of ASA and PCL via hydrogen bonding at the carboxyl groups, as seen in Figure 6. The 
detailed analysis of the formulation characterisation data can be found in the Supplementary 
Materials Section S1.1 
 
Figure 6. ATR-FTIR spectra of drug loaded PCL filaments in comparison to the raw material and the 
placebo filament. Shifted C-O stretching peak regions at ~1160 cm-1 and ~1290 cm-1 are highlighted in 
blue.  
It would be expected that a drug-polymer molten solution would exhibit different spreading 
behaviour when printed on the surface since the incorporation of the drug would be expected to 
alter the physical properties of the mix [35]. This was investigated by printing ASA-loaded PCL 
filaments at a median condition of 100 °C and 90 mm/s. Followed by determination of the average 
road width per layer. The results can be seen in Figure 7 against a placebo filament printed at the 
same conditions. No significant difference was seen in the nozzle and middle layer between the 
three drug-loaded filaments and the placebo filament. However, there is a significant increase in the 
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average road width of the first layer that was brought about by incorporation of ASA in PCL; 
printing at 90 mm/s and 100 °C showed an increase in the first layer road width from ≈ 390 µm to > 
600 µm. This is likely due to the presence of ASA in the PCL matrix decreasing the viscosity of the 
melt, allowing for a greater extent of spreading before the road completely solidifies. No significant 
difference was seen between the three drug-loaded formulations, this could be attributed to the 
ASA-PCL melt reaching the maximum possible wettability it can achieve on Kapton® before it 
solidifies, regardless of drug loading. Notably, the drug-loaded objects exhibited greater sticking to 
the platform than their placebo counterparts, requiring very careful peeling off the platform with a 
razor blade to avoid severely deforming the object printed. 
 
Figure 7. Impact of drug loading on the road width of the printed films. 
3.7. In Vitro Drug Release Studies 
Figure 8 shows the in vitro drug release rates for the 5%, 10%, and 15% ASA-loaded 
formulations in PCL. A significant difference in the release rate of the 5% formulation compared to 
its higher loading counterparts was observed. Both the 10% and 15% formulation achieved ~100% 
release in under 300 min. The 5% drug-loaded formulation, however, had released only ~30% of the 
drug after 8 h. As previously discussed, the 5% drug-loaded formulation was the only formulation 
in which the ASA was molecularly dispersed within the matrix of PCL, while both 10% and 15% 
drug-loaded contained phase separated crystalline ASA. This is further evidenced by the 
aforementioned differences in release rate. PCL is a biodegradable polymer that is commonly used 
for implantable, long-term release formulations [36]. It is insoluble in aqueous media, and only 
degrades over time via hydrolysis of its ester linkages in physiological conditions. In the 5% 
drug-loaded formulation, the ASA is molecularly dispersed within the polymer, thus the drug 
release relies on the slow diffusion of ASA molecules from the PCL matrices and the polymer 
degradation. On the other hand, the 10% and 15% drug-loaded formulations contain phase–
separated crystalline ASA which can dissolve much faster. No visible disintegration of the FDM 
printed films was observed over the 8 h dissolution tests. 
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Figure 8. In vitro drug release profiles of FDM printed PCL films containing 5%, 10%, and 15% ASA. 
3.8. Statistical Analysis 
The data above demonstrated the quality of the printed dosage form is a result of the complex 
interplay between different processing and materials factors. These factors also often interact such 
that varying the level of factors concurrently has a greater impact over a perceived measure of 
goodness than varying either parameter individually. Furthermore, while one can measure 
particular properties of the 3D printed object (such as weight, dimensions, road width, etc.) to be 
utilized as measures of goodness for parameter selection, this remains a non-straightforward 
process. Mainly because processing conditions that appear to produce a more favoured object when 
observing one measure of goodness fail when another measure of goodness is considered (i.e., 
weight versus dimensional authenticity). Therefore, it is clear that there exists a need for an 
overarching method for selecting the optimum printing conditions that will produce the objects with 
the greatest overall quality. For this purpose, we propose basing this method on a measure of 
goodness to determine the printing conditions which will produce objects with the highest overall 
printing reproducibility. Said conditions are those that will yield the minimum Summed Standard 
Deviation (SSD) score. This proposed SSD can be calculated by summing the standard deviations of 
each measured value at each condition. 
The SSD scores for all printing conditions can be seen in Figure 9. The processing parameters 
120 °C and 90 mm/s yielded the lowest SSD while 130 °C and 160 mm/s yielded the highest SSD. 
Objects printed at 90 mm/s notably had lower SSD scores for every single temperature than their 
counterparts printed at 30 mm/s and 160 mm/s. The SSD scores represent a figure of merit, which 
can be used to select a set of printing conditions which will give minimal overall variability. 
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Figure 9. Summed Standard Deviation (SSD) scores of printability of all tested conditions. 
While the SSD provides a quick method to determine the optimum printing conditions for a 
given filament, further statistical analysis techniques can be used to extract more information about 
the process parameters and how they interact to influence the process. Therefore, PCA was 
conducted as an exploratory data analysis tool to investigate the interplay between the different 
perceived quality parameters. 
Figure 10 shows the loadings plot of the measured responses in rotated space. Principal 
Component 1 (PC1) was found to describe object mass, road width, length, width, and the printer 
deposition index, corresponding to 57.77% of the total variance. Principal Component 2 (PC2) was 
found to describe object thickness, and first layer width, corresponding to 24.38% of the total 
variance. 
 
Figure 10. Loadings plot in rotated space. (FLW: first layer width. RW: road width). 
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As discussed in previous sections, object thickness and the first layer effect were found to 
correlate more strongly with printing temperature than with printing speed (Figures 4c and 5a), 
while object mass, length and width, and the FDM-MFI were found to vary more significantly in 
response to change in printing speed rather than printing temperature. Therefore, one may 
extrapolate that PC1 may be redubbed the speed axis, as it describes variance introduced due to 
change in printing speed. Similarly, PC2 may be named the temperature axis as the variables it 
describes are those that alter more significantly in response to changes in printing temperature. Since 
PC1 accounts for the majority of the total explained variance (57.77%), one may deduce that printing 
speed a more significant contributor to the perceived quality parameters of FDM printed objects 
than printing temperature. 
Observing the measured variables as described by the loadings plot allows for a more 
overarching look at how printing speed and temperature both influence perceived quality attributes, 
as well as how the quality attributes relate to one another. Object thickness and first layer width load 
opposite to each other on the temperature axis, suggesting the two are anti-correlated. This suggests 
that the spreading of the first layer not only increases its road width, but also decreases road height 
in the Z-axis. Furthermore, first layer width loads positively, while thickness loads negatively on the 
axis, indicating that wider road widths are brought about by higher temperatures, while greater 
object thickness is a result of lower printing temperature. Therefore, a conclusion can be drawn that 
printing at higher temperatures leads to a more drastic FLE, while printing at lower temperatures 
leads to thicker objects. 
Length, width, mass, FDM-MFI, and road width were all described by the speed axis. Length, 
width, and FDM-MFI being anti-correlated to mass and road width, with the former three loading 
positively, and the latter negatively, indicating that length, width, and the FDM-MFI are directly 
correlated to printing speed, while mass and road width are inversely correlated. The length/width 
versus road width correlation is an interesting one as it gives insight into the operation of the feeding 
motors, as well as printer accuracy; the anti-correlation between road width and printing speed 
suggests that at higher printing speeds, the printer is not feeding sufficient material to keep up with 
the demands of the higher printing speed, leading to the road being deposited to be tugged as the 
print head is moving, stretching it thinner (leading to a decrease in road width) and longer (leading 
to an increase in length/width). This argument relating printing speed and feeding speed suggests 
that, at higher print speeds, the printer is not providing enough material feed to faithfully replicate a 
print at lower speeds. Therefore, objects printed at higher speeds should have less mass than their 
lower speed counterparts. This was found to be true as mass loaded negatively on the speed axis, 
and was found to be anti-correlated to length, width, and FDM-MFI. The latter, which was found to 
increase relative to speed (Figure 3b) was, unsurprisingly, found to load positively on the speed axis. 
Figure 11 shows the biplot obtained when case scores were projected onto the loadings plot 
shown in Figure 10. The X-axis, denoting the scores of the cases against PC 1, unsurprisingly 
separates the cases into three clusters relative to printing speed, with three clusters showing clear 
separation between the 30 mm/s set, followed by 90 mm/s, and followed by 160 mm/s. The clustering 
pattern fits the argument presented prior relating printing speed to object mass and dimensions, as 
the leftmost cluster, falling on the “largest mass” quadrant of the biplot belonged to the 30 mm/s, 
then 90 mm/s, which was then followed by 160 mm/s, the “widest dimensions” set. Notably, there is 
less separation between the latter two sets than between 30 mm/s and 90 mm/s, which strongly 
mirrors the FDM-MFI results displayed in Figure 3b. 
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Figure 11. Biplot projecting the scores of the studied cases onto the response loadings. 
The Y-axis, which shows the scores loadings relative to PC2 (the temperature axis) describes 
quality parameters which are influenced by printing temperature (object thickness, and the FLE). 
While the clusters do not appear to offer any meaningful metric towards either parameter at first 
glance, closer observation reveals that both object thickness and FLE are not described within each 
cluster, but rather between the clusters. With respect to object thickness, looking at objects printed at 
the same temperature (i.e., 90 °C), the one printed at 160 mm/s was the thickest, followed by the 
object printed at 30 mm/s, with 90 mm/s coming in third. Similarly with respect to FLE, of the objects 
printed at 100 °C, the one printed at 160 mm/s had the largest FLE, followed by the one printed at 30 
mm/s, followed by the one printed at 90 mm/s. This inter-cluster pattern was found to apply to all 
the observed cases. This data pattern suggests that there may be either a more complex physical 
phenomenon, or a speed–temperature interaction that skews what is perceived as the impact 
printing temperature has on the quality parameters. 
Of the three clusters, the 90 mm/s group appears to show the least variance relative to change in 
printing temperature. This indicates that that printing speed further minimizes the significance of 
printing temperature. Furthermore, the 90 mm/s cluster was the most centered cluster with respect 
to the four quadrants of the biplot, indicating that 90 mm/s offers the best compromise between the 
opposing quality parameters. This sits in agreement with the result obtained from the SSD displayed 
in Figure 9, in which printing at a speed of 90 mm/s yielded the lowest SSD, regardless of printing 
temperature, indicating that higher reproducibility is achieved when printing at 90 mm/s. Therefore, 
one may extrapolate that, for the PCL filament used herein, printing at 90 mm/s offers the most 
predictable and reproducible results, making it the optimum printing speed for this filament. 
4. Conclusions 
The results of this study demonstrated the significant impact processing parameters have on 
some of the perceived quality attributes of 3D printed dosage forms (weight, dimensional 
authenticity, road width, and overall print reproducibility). For the printer used in the study, 
printing speed exhibited a more profound impact on the weight uniformity and dimension 
authenticity of the printed dosage forms than printing temperature. Printing temperature and the 
build plate surfaces were found to contribute significantly to the FLE. 
The repeatability and consistency of the calibration of the print was examined using the statistic 
variation observed in build plate leveling. The results confirmed that the build plate leveling is a 
source of significant operator-dependent error. This finding indicates the needs to redesign the build 
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plate leveling mechanism to allow more consistent and operator-independent calibration of the 
printer. 
The use of summed standard deviations (SSD) enables the calculation of a figure of merit 
indicating the most reproducible set of printing conditions, and by extension, the optimal printing 
parameters. 
PCA was used as factor exploration method to further investigate the impact of processing 
parameters on the quality attributed measured herein, and possibly explore some factor interplay 
that may not necessarily be obvious by looking at the impact processing parameters may have on a 
single quality parameter outside the context of the entire set of quality attributes. 
By using PCA, printing speed was found to explain more data variance than printing 
temperature. Factoring in that printing was not possible at a printing temperature of 70 ºC and 
printing speed ≥ 90 mm/s, we can conclude that, provided that the temperature is sufficient to 
overcome polymer viscosity, printing speed will have a greater contribution to the perceived quality 
parameters of the printed object. 
Printing speed was found to be negatively correlated with object road width, and more notably 
with object mass. Control of the latter being critical for accurate dosing in a pharmaceutical 
manufacturing context. Which leads us to deduce that increasing printing speed does not equal 
increased printing throughput, and is not a valid method for the scaling-up of a pharmaceutical 
FDM printing process. 
The use of PCA did prove to be an effective chemometric method to determine the optimum 
printing conditions for the filament studied herein, as it revealed the processing parameters that 
produce objects that offer the best compromise between the extremes of all the perceived quality 
parameters. Said processing conditions were deemed to be the optimum because they offer the most 
reproducible and predictable prints, and not because they match a desired target value. 
For pharmaceutical applications, the control of such impacts should be thoroughly understood 
as it can affect the performance of the printed formulation. These results brought to the conclusion of 
that careful engineering for a pharmaceutically suitable FDM 3D printer should be treated as a 
priority for making the shift of FDM 3D printing from proof-of-concept to industrial application. 
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images may be resized for viewing the full details of the measurements. 
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